~~<i id='D2596230FF'><strike id='D2596230FF'><tt id='D2596230FF'><pre id='D2596230FF'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：comprehensive 2025-10-02 21:33:00 Page View：851

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： A letter from the executive editor: STAT UnitedHealth investigation
Next article： The high cost of giving birth even with insurance

explore

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

How housing is health care on Long Island

LongIslandisinthemidstofahousingcrisis.Justlikeinmanyotherpartsofthecountry,LongIslandersarehavingat

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Study suggests Covid rebound is far more common with Paxlovid than without

AdobeAsmallandpreliminarystudypublishedMondayseemstoindicatethatpatientsreceivingthedrugPaxlovidaref